Leukeran

Chlorambucil, the active ingredient in Leukeran, is a alkylating agent presented as a tablet for oral use. It treats chronic lymphocytic leukemia, Hodgkin's lymphoma and other lymphoid malignancies in adult patients.

GNH USA supplies Leukeran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leukeran is an alkylating antineoplastic agent used in lymphoid cancers.

- Chronic lymphocytic leukemia: improves disease control and can extend survival. - Hodgkin's lymphoma: contributes to remission when incorporated into combination chemotherapy. - Other lymphoid malignancies: provides antineoplastic activity across various lymphoid cancer subtypes.

Leukeran may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Decreased blood cell counts (anemia, leukopenia, thrombocytopenia) - Loss of appetite - Alopecia (hair loss) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe neutropenia leading to infection - Secondary malignancies such as acute leukemia - Significant hemorrhage due to thrombocytopenia - Pulmonary fibrosis or interstitial lung disease - Hepatotoxicity with elevated liver enzymes - Life‑threatening allergic reactions (anaphylaxis).

Before initiating therapy, clinicians should assess baseline health and monitor patients regularly.

- Monitor blood counts: perform complete blood counts frequently to detect myelosuppression. - Assess liver function: periodic liver enzyme tests are recommended. - Evaluate renal function: adjust therapy if significant impairment is present. - Avoid use in patients with known hypersensitivity to alkylating agents. - Pregnancy and lactation: risk unknown; avoid use in pregnant or breastfeeding women. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Leukeran can interact with several medicines, influencing safety or effectiveness.

Major Interactions (Avoid): - Concurrent myelosuppressive agents (e.g., cyclophosphamide) may cause profound bone marrow suppression. - Live vaccines: increased risk of severe infection. - Strong CYP450 inducers (e.g., rifampin, carbamazepine) may reduce chlorambucil exposure.

Moderate Interactions (Monitor Closely): - NSAIDs may increase gastrointestinal irritation. - Anticoagulants can heighten bleeding risk. - Allopurinol may enhance chlorambucil toxicity. - Antacids containing aluminum or magnesium may affect absorption.